تداخلات كابتوبريل

كابتوبريل (Capoten؛ من فئة مثبطات الإنزيم المحول للأنجيوتنسين (ACE)): 264 تداخلًا موثّقًا في نشرات FDA وصحائف الوقائع التي نفهرسها، وتوزيعها: شديدة 65، متوسطة 154، طفيفة 45، وحالات تفيد فيها نشرة بعدم وجود تداخل مهم 0. كل مُدخل أدناه يقتبس الجملة التي يستند إليها. صفحة الدواء هذه نقطة انطلاق، وليست حكمًا على حالتك.

كيف يبدو كابتوبريل

كل النسخ (28)
قرص كابتوبريل 12.5 mg: أبيض، مستدير، 5 مم، محزّز، النقش W على أحد الوجهين و902 على الوجه الآخر.
W / 902
12.5 mg · أبيض · مستدير · 5 مم · محزّز
Wockhardt
قرص كابتوبريل 25 mg: أبيض، مستدير، 7 مم، النقش W على أحد الوجهين و903 على الوجه الآخر.
W / 903
25 mg · أبيض · مستدير · 7 مم
Wockhardt
قرص كابتوبريل 50 mg: أبيض، مستدير، 8 مم، محزّز، النقش W على أحد الوجهين و904 على الوجه الآخر.
W / 904
50 mg · أبيض · مستدير · 8 مم · محزّز
Wockhardt
قرص كابتوبريل 50 mg: أبيض، بيضاوي، 8 مم، محزّز، النقش WW على أحد الوجهين و173 على الوجه الآخر.
WW / 173
50 mg · أبيض · بيضاوي · 8 مم · محزّز
Hikma Pharmaceuticals

رسوم مُنشأة من قوائم المنتجات في نشرات FDA: اللون والشكل والحجم والنقش. 28 نسخة موثّقة من 12 شركة مسوّقة.

تداخلات من النشرة

تداخلات شديدة (65)

  • أباتاسبتمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • إبتيفيباتيدمضادات الصفيحاتشديد

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (نشرة إبتيفيباتيد، موانع الاستعمال)

  • أبروسيتينيبمثبطات JAKشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • أداليمومابمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • إربيسارتان وهيدروكلوروثيازيدحاصرات مستقبلات الأنجيوتنسين II (ARB)شديد

    In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with ACE inhibitors has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. (نشرة إربيسارتان وهيدروكلوروثيازيد، التحذيرات والاحتياطات)

  • أزاثيوبرينمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • البوتاسيومفيتامينات ومعادنشديد

    هذه الأدوية تقلّل إطراح البوتاسيوم؛ وإضافة مكملات البوتاسيوم أو بدائل الملح قد تسبب فرط بوتاسيوم الدم، وهو يؤثر في نظم القلب. (NIH Office of Dietary Supplements, Potassium)

  • أليسكيرينخافضات ضغط الدمشديد

    Do not co-administer aliskiren with captopril tablets in patients with diabetes (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، موانع الاستعمال)

  • أليمتوزومابمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • أملوديبين وبينازيبريلحاصرات قنوات الكالسيوم من ثنائيات هيدروبيريدينشديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • أملوديبين وفالسارتانحاصرات قنوات الكالسيوم من ثنائيات هيدروبيريدينشديد

    Do not administer captopril tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، موانع الاستعمال)

  • إنالابريلمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • إنالابريل وهيدروكلوروثيازيدمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • إنالابريلاتمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • إنفليكسيمابمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • أوباداسيتينيبمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • أوستيكينومابمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • أوكريليزومابمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • إيتانرسبتمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • إيفيروليموسمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • باريسيتينيبمثبطات JAKشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • بونيسيمودمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • بيريندوبريلمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • بيميكروليموسمثبطات الكالسينيورينشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • بينازيبريلمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • بينازيبريل وهيدروكلوروثيازيدمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • تادالافيلمثبطات PDE5شديد

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (نشرة تادالافيل، التحذيرات والاحتياطات)

  • تاكروليموسمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • تراندولابريلمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • توسيليزومابمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • توفاسيتينيبمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • تيريفلونوميدمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • تيلميسارتانحاصرات مستقبلات الأنجيوتنسين II (ARB)شديد

    Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker ( 5.6 ) (نشرة تيلميسارتان، التحذيرات والاحتياطات)

  • تيلميسارتان وأملوديبينحاصرات مستقبلات الأنجيوتنسين II (ARB)شديد

    Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

  • تيلميسارتان وهيدروكلوروثيازيدحاصرات مستقبلات الأنجيوتنسين II (ARB)شديد

    Patients who received the combination of ARB and ACE inhibitor did not obtain any additional benefit (no additional reduction of risk of cardiovascular death, myocardial infarction, stroke, or hospitalization from heart failure) compared to ARB monotherapy or ACE inhibitor monotherapy, but experienced an increased incidence of renal dysfunction (e.g., acute renal… (نشرة تيلميسارتان وهيدروكلوروثيازيد، التداخلات الدوائية)

  • ثنائي ميثيل الفوماراتمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • راميبريلمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • ريتليسيتينيبمثبطات JAKشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • ريتوكسيمابمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • ساكوبيتريل وفالسارتانحاصرات مستقبلات الأنجيوتنسين II (ARB)شديد

    Captopril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (نشرة كابتوبريل، موانع الاستعمال)

  • سيروليموسمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • سيكلوسبورينمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • سيكلوفوسفاميدمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • سيكوكينومابمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • غوسيلكومابمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • فالسارتانحاصرات مستقبلات الأنجيوتنسين II (ARB)شديد

    Do not administer captopril tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، موانع الاستعمال)

  • فالسارتان وهيدروكلوروثيازيدحاصرات مستقبلات الأنجيوتنسين II (ARB)شديد

    Do not administer captopril tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، موانع الاستعمال)

  • فوسينوبريلمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • فوسينوبريل وهيدروكلوروثيازيدمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • فينغوليمودمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • كانديسارتانحاصرات مستقبلات الأنجيوتنسين II (ARB)شديد

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (نشرة كانديسارتان، التداخلات الدوائية)

  • كلادريبينمضادات المستقلباتشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • كلوزابينمضادات الذهانشديد

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (نشرة كلوزابين، تحذير مؤطر)

  • كينابريلمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • كينابريل وهيدروكلوروثيازيدمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • ليزينوبريلمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • ليزينوبريل وهيدروكلوروثيازيدمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • ليفلونوميدمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • موكسيبريلمثبطات الإنزيم المحول للأنجيوتنسين (ACE)شديد

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (نشرة كابتوبريل، موانع الاستعمال)

  • ميتولازونمدرات البول الثيازيديةشديد

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (نشرة ميتولازون، التحذيرات)

  • ميثوتريكساتمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • ميركابتوبورينمضادات المستقلباتشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • ميكوفينولاتمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

  • مينوكسيديلموسعات الأوعيةشديد

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (نشرة مينوكسيديل، تحذير مؤطر)

  • ناتاليزومابمثبطات المناعةشديد

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

تداخلات متوسطة (154)

  • إبليرينونمضادات الألدوستيرونمتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • أتوموكسيتينمثبطات استرداد النورإبينفرينمتوسط

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (نشرة أتوموكسيتين، التداخلات الدوائية)

  • أتينولولحاصرات بيتامتوسط

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (نشرة أتينولول، التحذيرات)

  • أتينولول وكلورثاليدونحاصرات بيتامتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • أدرينالينمحاكيات الوديمتوسط

    Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. (نشرة أدرينالين، التداخلات الدوائية)

  • إربيسارتانحاصرات مستقبلات الأنجيوتنسين II (ARB)متوسط

    Drug Interactions Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة كابتوبريل، التداخلات الدوائية)

  • أرمودافينيلمنبهات الجهاز العصبي المركزيمتوسط

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (نشرة أرمودافينيل، التحذيرات والاحتياطات)

  • أريبيبرازولمضادات الذهانمتوسط

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (نشرة أريبيبرازول، التداخلات الدوائية)

  • أزيلسارتانحاصرات مستقبلات الأنجيوتنسين II (ARB)متوسط

    Drug Interactions Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة كابتوبريل، التداخلات الدوائية)

  • أسبرينمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • أسبرين وديبيريدامولمضادات الصفيحاتمتوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • إسمولولحاصرات بيتامتوسط

    Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (نشرة إسمولول، التداخلات الدوائية)

  • أسيتازولاميدمثبطات الأنهيدراز الكربونيةمتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • أسينابينمضادات الذهانمتوسط

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة أسينابين، التحذيرات والاحتياطات)

  • أفانافيلمثبطات PDE5متوسط

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (نشرة أفانافيل، التحذيرات والاحتياطات)

  • ألبروستاديلنظائر البروستاغلاندينمتوسط

    Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

  • In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (نشرة ألتيبلاز، التداخلات الدوائية)

  • ألفوزوسينحاصرات ألفامتوسط

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (نشرة ألفوزوسين، التحذيرات والاحتياطات)

  • أملوديبين وأولميسارتانحاصرات قنوات الكالسيوم من ثنائيات هيدروبيريدينمتوسط

    Drug Interactions Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة كابتوبريل، التداخلات الدوائية)

  • أميلوريدمدرات البول الحافظة للبوتاسيوممتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • إنداباميدمدرات البول الثيازيديةمتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • إندوميثاسينمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • إنسولين أسبارتالإنسولينمتوسط

    Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. (نشرة إنسولين أسبارت، التداخلات الدوائية)

  • إنسولين ديتيميرالإنسولينمتوسط

    Table 6: Clinically Significant Drug Interactions with LEVEMIR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide… (نشرة إنسولين ديتيمير، التداخلات الدوائية)

  • إنسولين ديغلوديكالإنسولينمتوسط

    Table 5: Clinically Significant Drug Interactions with Insulin Degludec Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide… (نشرة إنسولين ديغلوديك، التداخلات الدوائية)

  • إنسولين عادي (بشري)الإنسولينمتوسط

    Clinically Significant Drug Interactions with AFREZZA Antidiabetic agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor… (نشرة إنسولين عادي (بشري)، التداخلات الدوائية)

  • إنسولين غلارجينالإنسولينمتوسط

    Table 8: Clinically Significant Drug Interactions with Insulin Glargine-yfgn Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide… (نشرة إنسولين غلارجين، التداخلات الدوائية)

  • إنسولين ليسبروالإنسولينمتوسط

    Clinically Significant Drug Interactions with LYUMJEV Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (نشرة إنسولين ليسبرو، التداخلات الدوائية)

  • أورفينادرين وأسبرين وكافيينمرخيات العضلاتمتوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • أوكسابروزينمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • أولانزابينمضادات الذهانمتوسط

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (نشرة أولانزابين، التحذيرات والاحتياطات)

  • أولانزابين وفلوكسيتينمضادات الذهانمتوسط

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (نشرة أولانزابين وفلوكسيتين، التحذيرات والاحتياطات)

  • أولميسارتانحاصرات مستقبلات الأنجيوتنسين II (ARB)متوسط

    Drug Interactions Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة كابتوبريل، التداخلات الدوائية)

  • أولميسارتان وأملوديبين وهيدروكلوروثيازيدحاصرات مستقبلات الأنجيوتنسين II (ARB)متوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • أولميسارتان وهيدروكلوروثيازيدحاصرات مستقبلات الأنجيوتنسين II (ARB)متوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • إيبوبروستينولنظائر البروستاغلاندينمتوسط

    Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

  • إيبوبروفينمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • إيبوبروفين وفاموتيدينمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (نشرة إيبويتين ألفا، التحذيرات والاحتياطات)

  • إيتودولاكمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

  • Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

  • Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

  • إيلوبيريدونمضادات الذهانمتوسط

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (نشرة إيلوبيريدون، التحذيرات والاحتياطات)

  • بابافيرينموسعات الأوعيةمتوسط

    Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

  • باراسيتامول وإيبوبروفينمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (نشرة بازوبانيب، التحذيرات والاحتياطات)

  • باليبيريدونمضادات الذهانمتوسط

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (نشرة باليبيريدون، التحذيرات والاحتياطات)

  • برازوسينحاصرات ألفامتوسط

    Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (نشرة برازوسين، التحذيرات)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (نشرة برومفينيرامين وسودوإيفيدرين وديكستروميثورفان، التداخلات الدوائية)

  • بروموكريبتينناهضات الدوبامينمتوسط

    Use caution in patients taking antihypertensive medications. (نشرة بروموكريبتين، التحذيرات والاحتياطات)

  • بريغابالينمضادات الاختلاجمتوسط

    In addition, patients who are taking other drugs associated with angioedema (e.g., angiotensin converting enzyme inhibitors [ACE-inhibitors]) may be at increased risk of developing angioedema. (نشرة بريغابالين، التحذيرات والاحتياطات)

  • بريكسبيبرازولمضادات الذهانمتوسط

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (نشرة بريكسبيبرازول، التحذيرات والاحتياطات)

  • بريمونيدينناهضات ألفا الأدريناليةمتوسط

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (نشرة بريمونيدين، التداخلات الدوائية)

  • بريمونيدين وتيمولولناهضات ألفا الأدريناليةمتوسط

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (نشرة بريمونيدين وتيمولول، التداخلات الدوائية)

  • بنتوكسيفيلينالميثيل زانثيناتمتوسط

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (نشرة بنتوكسيفيلين، التداخلات الدوائية)

  • بنزفيتامينمنبهات الجهاز العصبي المركزيمتوسط

    Amphetamines may decrease the hypotensive effect of antihypertensives. (نشرة بنزفيتامين، التداخلات الدوائية)

  • بوتالبيتال وأسبرين وكافيينالباربيتوراتمتوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (نشرة بورتيزوميب، التحذيرات والاحتياطات)

  • بوليستيرين سلفونات الصوديوممكملات البوتاسيوممتوسط

    Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. (نشرة كابتوبريل، التداخلات الدوائية)

  • بوميتانيدمدرات العروةمتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • بيروكسيكاممضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • بيسوبرولولحاصرات بيتامتوسط

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (نشرة بيسوبرولول، التحذيرات)

  • Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • بيوغليتازون وغليميبيريدالثيازوليدينديوناتمتوسط

    …glimepiride tablets, increasing the susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine,… (نشرة بيوغليتازون وغليميبيريد، التداخلات الدوائية)

  • ترازودونمضادات الاكتئابمتوسط

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (نشرة ترازودون، التحذيرات والاحتياطات)

  • تريامتيرينمدرات البول الحافظة للبوتاسيوممتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • تريامتيرين وهيدروكلوروثيازيدمدرات البول الحافظة للبوتاسيوممتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • تريبروستينيلنظائر البروستاغلاندينمتوسط

    Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

  • تستوستيرونالأندروجيناتمتوسط

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (نشرة تستوستيرون، التحذيرات والاحتياطات)

  • توراسيميدمدرات العروةمتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • Monitor serum potassium during concomitant therapy with ( 7.2 ): Angiotensin receptor blockers Angiotensin converting enzyme inhibitors Potassium sparing diuretics 7.1 CYP3A Inhibitors and Inducers Strong CYP3A Inhibitors Tolvaptan's AUC was 5.4 times as large and C max was 3.5 times as large after co-administration of tolvaptan and 200 mg ketoconazole [see Warnings… (نشرة تولفابتان، التداخلات الدوائية)

  • تولميتينمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • تيرازوسينحاصرات ألفامتوسط

    Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (نشرة تيرازوسين، التحذيرات والاحتياطات)

  • Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • حمض الإيثاكرينيكمدرات العروةمتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • حمض الميفيناميكمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • دالفامبريدينمكملات البوتاسيوممتوسط

    Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. (نشرة كابتوبريل، التداخلات الدوائية)

  • دروسبيرينون وإيثينيل إستراديولموانع الحمل الفمويةمتوسط

    Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (نشرة دروسبيرينون وإيثينيل إستراديول، التحذيرات والاحتياطات)

  • دوفيتيليدمضادات اضطراب النظممتوسط

    Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (نشرة دوفيتيليد، التداخلات الدوائية)

  • دولوكسيتينمثبطات استرداد السيروتونين والنورإبينفرين (SNRI)متوسط

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (نشرة دولوكسيتين، التحذيرات والاحتياطات)

  • ديثيل بروبيونمنبهات الجهاز العصبي المركزيمتوسط

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (نشرة ديثيل بروبيون، التداخلات الدوائية)

  • ديفلونيزالمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • ديكسميثيل فينيداتمنبهات الجهاز العصبي المركزيمتوسط

    • Antihypertensive Drugs: Monitor blood pressure. (نشرة ديكسميثيل فينيدات، التداخلات الدوائية)

  • ديكلوفيناكمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • ديكلوفيناك وميزوبروستولمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • ريباغلينيدالميغليتينيداتمتوسط

    Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. (نشرة كابتوبريل، التداخلات الدوائية)

  • ريسبيريدونمضادات الذهانمتوسط

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (نشرة ريسبيريدون، التحذيرات والاحتياطات)

  • ريوسيغواتموسعات الأوعيةمتوسط

    Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

  • زيبراسيدونمضادات الذهانمتوسط

    Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (نشرة زيبراسيدون، التحذيرات والاحتياطات)

  • سالسالاتمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • سبيرونولاكتونمضادات الألدوستيرونمتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • سبيرونولاكتون وهيدروكلوروثيازيدمضادات الألدوستيرونمتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • سترات البوتاسيوممكملات البوتاسيوممتوسط

    Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. (نشرة كابتوبريل، التداخلات الدوائية)

  • سلفاميثوكسازول وتريميثوبريمالسلفوناميداتمتوسط

    In the literature, three cases of hyperkalemia in elderly patients have been reported after concomitant intake of sulfamethoxazole/trimethoprim and an angiotensin converting enzyme inhibitor. (نشرة سلفاميثوكسازول وتريميثوبريم، التداخلات الدوائية)

  • Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (نشرة سورافينيب، التحذيرات والاحتياطات)

  • سولينداكمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • سوماتريبتان ونابروكسينالتريبتاناتمتوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • Initiate and/or adjust antihypertensive therapy as appropriate. (نشرة سونيتينيب، التحذيرات والاحتياطات)

  • سيكلوبنزابرينمرخيات العضلاتمتوسط

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (نشرة سيكلوبنزابرين، التداخلات الدوائية)

  • سيلدينافيلمثبطات PDE5متوسط

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (نشرة سيلدينافيل، التحذيرات والاحتياطات)

  • سيلودوسينحاصرات ألفامتوسط

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (نشرة سيلودوسين، التحذيرات والاحتياطات)

  • سيليكوكسيبمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • غليبنكلاميدالسلفونيل يوريامتوسط

    Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking… (نشرة غليبنكلاميد، التداخلات الدوائية)

  • غليبيزيدالسلفونيل يوريامتوسط

    …following are examples of medication that may increase the glucose lowering effect of GLUCOTROL XL, increase the susceptibility to and/or intensity of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin… (نشرة غليبيزيد، التداخلات الدوائية)

  • غليميبيريدالسلفونيل يوريامتوسط

    …including glimepiride, increasing the susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine,… (نشرة غليميبيريد، التداخلات الدوائية)

  • فاردينافيلمثبطات PDE5متوسط

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (نشرة فاردينافيل، التداخلات الدوائية)

  • فلوربيبروفينمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • فوروسيميدمدرات العروةمتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • فيراباميلحاصرات قنوات الكالسيوممتوسط

    Antihypertensive Agents Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers) will usually have an additive effect on lowering blood pressure. (نشرة فيراباميل، التداخلات الدوائية)

  • فيريسيغواتموسعات الأوعيةمتوسط

    Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

  • فينلافاكسينمثبطات استرداد السيروتونين والنورإبينفرين (SNRI)متوسط

    Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

  • فينوبروفينمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • فينيلزينمثبطات أكسيداز أحادي الأمين (MAOI)متوسط

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (نشرة فينيلزين، التحذيرات)

  • فينيليفرينمزيلات الاحتقانمتوسط

    Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (نشرة فينيليفرين، التداخلات الدوائية)

  • Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (نشرة كاربيدوبا، التداخلات الدوائية)

  • كاربيدوبا وليفودوباالأدوية الدوبامينيةمتوسط

    Antihypertensive drugs: May cause symptomatic postural hypotension. (نشرة كاربيدوبا وليفودوبا، التداخلات الدوائية)

  • كاربيدوبا وليفودوبا وإنتاكابونالأدوية الدوبامينيةمتوسط

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (نشرة كاربيدوبا وليفودوبا وإنتاكابون، التداخلات الدوائية)

  • كارفيديلولحاصرات بيتامتوسط

    COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (نشرة كارفيديلول، التحذيرات والاحتياطات)

  • كاريبرازينمضادات الذهانمتوسط

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (نشرة كاريبرازين، التحذيرات والاحتياطات)

  • كانديسارتان وهيدروكلوروثيازيدحاصرات مستقبلات الأنجيوتنسين II (ARB)متوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • كلورثاليدونمدرات البول الثيازيديةمتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • كلوروثيازيدمدرات البول الثيازيديةمتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • كلوريد البوتاسيوممكملات البوتاسيوممتوسط

    Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. (نشرة كابتوبريل، التداخلات الدوائية)

  • كويتيابينمضادات الذهانمتوسط

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (نشرة كويتيابين، التحذيرات والاحتياطات)

  • كيتوبروفينمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • كيتورولاكمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • لانثانومرابطات الفوسفاتمتوسط

    Examples of relevant classes of compounds where antacids have been demonstrated to reduce bioavailability include antibiotics (such as quinolones, ampicillin, and tetracyclines), thyroid hormones, ACE inhibitors, statin lipid regulators, and anti-malarials. (نشرة لانثانوم، التداخلات الدوائية)

  • لوراسيدونمضادات الذهانمتوسط

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (نشرة لوراسيدون، التحذيرات والاحتياطات)

  • لوسارتانحاصرات مستقبلات الأنجيوتنسين II (ARB)متوسط

    Drug Interactions Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة كابتوبريل، التداخلات الدوائية)

  • لوسارتان وهيدروكلوروثيازيدحاصرات مستقبلات الأنجيوتنسين II (ARB)متوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • لوماتيبيرونمضادات الذهانمتوسط

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

  • ليثيومالأدوية السيروتونينيةمتوسط

    Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. (نشرة كابتوبريل، التداخلات الدوائية)

  • مودافينيلمنبهات الجهاز العصبي المركزيمتوسط

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (نشرة مودافينيل، التحذيرات والاحتياطات)

  • Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • ميثيل فينيداتمنبهات الجهاز العصبي المركزيمتوسط

    Antihypertensive Drugs: Monitor blood pressure. (نشرة ميثيل فينيدات، التداخلات الدوائية)

  • ميرتازابينمضادات الاكتئابمتوسط

    REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (نشرة ميرتازابين، التحذيرات والاحتياطات)

  • ميكاميلامينخافضات ضغط الدممتوسط

    The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (نشرة ميكاميلامين، التداخلات الدوائية)

  • ميلوكسيكاممضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • نابروكسينمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • نابروكسين وإيزوميبرازولمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • نابوميتونمضادات الالتهاب غير الستيرويدية (NSAIDs)متوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • ناتيغلينيدالميغليتينيداتمتوسط

    Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. (نشرة كابتوبريل، التداخلات الدوائية)

  • نالديميدينمضادات الأفيونياتمتوسط

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (نشرة نالديميدين، التداخلات الدوائية)

  • نياسينمتوسط

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (نشرة نياسين، التداخلات الدوائية)

  • نيتروبروسيدموسعات الأوعيةمتوسط

    Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

  • نيتروغليسرينالنتراتمتوسط

    Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

  • نيفيديبينحاصرات قنوات الكالسيوم من ثنائيات هيدروبيريدينمتوسط

    ACE Inhibitors Benazepril: In healthy volunteers receiving single dose of 20 mg nifedipine ER and benazepril 10 mg, the plasma concentrations of benazeprilat and nifedipine in the presence and absence of each other were not statistically significantly different. (نشرة نيفيديبين، التداخلات الدوائية)

  • نيموديبينحاصرات قنوات الكالسيوم من ثنائيات هيدروبيريدينمتوسط

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (نشرة نيموديبين، التداخلات الدوائية)

  • هيدرالازينموسعات الأوعيةمتوسط

    Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

  • هيدروكلوروثيازيدمدرات البول الثيازيديةمتوسط

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (نشرة كابتوبريل، التحذيرات)

  • هيدروكودون وإيبوبروفينالأفيونياتمتوسط

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration… (نشرة كابتوبريل، التداخلات الدوائية)

  • Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (نشرة يوديد البوتاسيوم، التداخلات الدوائية)

إشارات طفيفة (45)

  • أرتيكايين وأدرينالينأدوية التخدير الموضعيطفيف

    Emergency therapy, including but not necessarily limited to, subcutaneous administration of a 1:1000 solution of epinephrine should be promptly instituted. (نشرة كابتوبريل، التحذيرات)

  • إسراديبينحاصرات قنوات الكالسيوم من ثنائيات هيدروبيريدينطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • أسيبوتولولحاصرات بيتاطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • ألوبيورينولمثبطات أكسيداز الزانثينطفيف

    In foreign marketing experience in patients with renal failure, use of allopurinol concomitantly with captopril has been associated with neutropenia but this association has not appeared in U.S. reports. (نشرة كابتوبريل، التحذيرات)

  • أملوديبينحاصرات قنوات الكالسيوم من ثنائيات هيدروبيريدينطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • أملوديبين وأتورفاستاتينحاصرات قنوات الكالسيوم من ثنائيات هيدروبيريدينطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • إيفيدرينمحاكيات الوديطفيف

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (نشرة إيفيدرين، التداخلات الدوائية)

  • ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (نشرة إيكاتيبانت، التداخلات الدوائية)

  • بروبرانولولحاصرات بيتاطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • بروتريبتيلينمضادات الاكتئاب ثلاثية الحلقاتطفيف

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (نشرة بروتريبتيلين، التحذيرات)

  • بروكاييناميدمضادات اضطراب النظمطفيف

    About half of the reported cases had serum creatinine ≥ 1.6 mg/dL and more than 75 percent were in patients also receiving procainamide. (نشرة كابتوبريل، التحذيرات)

  • بروكلوربيرازينمضادات الذهانطفيف

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (نشرة بروكلوربيرازين، الاحتياطات)

  • بريلوكايين وأدرينالينأدوية التخدير الموضعيطفيف

    Emergency therapy, including but not necessarily limited to, subcutaneous administration of a 1:1000 solution of epinephrine should be promptly instituted. (نشرة كابتوبريل، التحذيرات)

  • بوبيفاكايين وأدرينالينأدوية التخدير الموضعيطفيف

    Emergency therapy, including but not necessarily limited to, subcutaneous administration of a 1:1000 solution of epinephrine should be promptly instituted. (نشرة كابتوبريل، التحذيرات)

  • بوتورفانولالأفيونياتطفيف

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (نشرة بوتورفانول، التحذيرات)

  • بيتاكسولولحاصرات بيتاطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • بيندولولحاصرات بيتاطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • تريفلوبيرازينمضادات الذهانطفيف

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (نشرة تريفلوبيرازين، الاحتياطات)

  • تيزانيدينمرخيات العضلاتطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • دوكسازوسينحاصرات ألفاطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • ديجوكسينغليكوزيدات الديجيتالطفيف

    Cardiac Glycosides In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found. (نشرة كابتوبريل، التداخلات الدوائية)

  • ديسوجيستريل وإيثينيل إستراديولموانع الحمل الفمويةطفيف

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (نشرة ديسوجيستريل وإيثينيل إستراديول، التحذيرات)

  • ديسيبرامينمضادات الاكتئاب ثلاثية الحلقاتطفيف

    This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (نشرة ديسيبرامين، التحذيرات)

  • ديكستروأمفيتامينمنبهات الجهاز العصبي المركزيطفيف

    Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (نشرة ديكستروأمفيتامين، التداخلات الدوائية)

  • ديلتيازيمحاصرات قنوات الكالسيومطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • سيدوفوفيرمضادات الفيروساتطفيف

    Drug Interactions Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline,… (نشرة سيدوفوفير، التداخلات الدوائية)

  • Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (نشرة سيكلوسيليكات الزركونيوم الصوديوم، التداخلات الدوائية)

  • غوانفاسينناهضات ألفا الأدريناليةطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • فيلوديبينحاصرات قنوات الكالسيوم من ثنائيات هيدروبيريدينطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • فيناستيريدمثبطات 5-ألفا ريدوكتازطفيف

    …specific interaction studies were not performed, PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory… (نشرة فيناستيريد، التداخلات الدوائية)

  • فينوكسي بنزامينحاصرات ألفاطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • كلوربرومازينمضادات الذهانطفيف

    Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (نشرة كلوربرومازين، التحذيرات)

  • كلونيدينناهضات ألفا الأدريناليةطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • لابيتالولحاصرات بيتاطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • لوفيكسيدينناهضات ألفا الأدريناليةطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • ليدوكايين وأدرينالينأدوية التخدير الموضعيطفيف

    Emergency therapy, including but not necessarily limited to, subcutaneous administration of a 1:1000 solution of epinephrine should be promptly instituted. (نشرة كابتوبريل، التحذيرات)

  • ميتوبرولولحاصرات بيتاطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • ميثيل دوباخافضات ضغط الدمطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • ميكسيليتينمضادات اضطراب النظمطفيف

    In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (نشرة ميكسيليتين، التداخلات الدوائية)

  • ميلرينونمثبطات PDE3طفيف

    …been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (نشرة ميلرينون، التداخلات الدوائية)

  • نادولولحاصرات بيتاطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • نورتريبتيلينمضادات الاكتئاب ثلاثية الحلقاتطفيف

    The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

  • نيبيفولولحاصرات بيتاطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • نيسولديبينحاصرات قنوات الكالسيوم من ثنائيات هيدروبيريدينطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

  • نيكارديبينحاصرات قنوات الكالسيوم من ثنائيات هيدروبيريدينطفيف

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (نشرة كابتوبريل، التحذيرات)

افحص كابتوبريل مع كل ما تتناوله. أضف قائمتك كاملة؛ تُفحص كل الأزواج دفعة واحدة.

افتح في الفاحص

ليست نصيحة طبية. درجة الشدة تعكس صياغة النشرة، لا ظروفك. فالتنبيه «الشديد» قد يكون أمرًا معتادًا تحت الإشراف، والتنبيه «الطفيف» قد يكون مهمًا عند الجرعات العالية. اسأل صيدليًا.